RESEARCH ARTICLE Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys Daniel B Larremore1,2*, Bailey K Fosdick3, Kate M Bubar4,5, Sam Zhang4, Stephen M Kissler6, C Jessica E Metcalf7, Caroline O Buckee8,9, Yonatan H Grad6* 1Department of Computer Science, University of Colorado Boulder, Boulder, United States; 2BioFrontiers Institute, University of Colorado Boulder, Boulder, United States; 3Department of Statistics, Colorado State University, Fort Collins, United States; 4Department of Applied Mathematics, University of Colorado Boulder, Boulder, United States; 5IQ Biology Program, University of Colorado Boulder, Boulder, United States; 6Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, United States; 7Department of Ecology and Evolutionary Biology and the Woodrow Wilson School, Princeton University, Princeton, United States; 8Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, United States; 9Center for Communicable Disease Dynamics, Harvard T.H. Chan School of Public Health, Boston, United States Abstract Establishing how many people have been infected by SARS-CoV-2 remains an urgent priority for controlling the COVID-19 pandemic. Serological tests that identify past infection can be used to estimate cumulative incidence, but the relative accuracy and robustness of various *For correspondence: sampling strategies have been unclear. We developed a flexible framework that integrates
[email protected]